Literature DB >> 21327573

Pathophysiology and treatment options for cardiac anorexia.

Marat Fudim1, Gabriel Wagman, Rebecca Altschul, Evin Yucel, Michelle Bloom, Timothy J Vittorio.   

Abstract

The anorexia-cachexia syndrome (ACS) occurs in many chronic illnesses, such as cancer, AIDS, and chronic obstructive pulmonary disease in addition to chronic congestive heart failure (CHF). Comparable to other chronic states, the ACS complicates CHF and impacts its prognosis; however, the available treatment options for this syndrome remain unsatisfactory. This review article focuses on the complex pathophysiology of cardiac anorexia. We focus on the recent data demonstrating the relationships between central appetite-regulating structures, inflammatory processes, and neurohormonal activation, and their respective roles in the development of anorexia. We then describe the different treatment options and discuss some future prospects for the management for cardiac anorexia.

Entities:  

Mesh:

Year:  2011        PMID: 21327573     DOI: 10.1007/s11897-011-0049-5

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  86 in total

1.  Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.

Authors:  M A Joppa; K R Gogas; A C Foster; S Markison
Journal:  Peptides       Date:  2007-01-03       Impact factor: 3.750

Review 2.  Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives.

Authors:  Klaus K Witte; Andrew L Clark
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.214

3.  Endotoxin and immune activation in chronic heart failure: a prospective cohort study.

Authors:  J Niebauer; H D Volk; M Kemp; M Dominguez; R R Schumann; M Rauchhaus; P A Poole-Wilson; A J Coats; S D Anker
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321

4.  Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia.

Authors:  W Doehner; C D Pflaum; M Rauchhaus; I F Godsland; K Egerer; M Cicoira; V G Florea; R Sharma; A P Bolger; A J Coats; S D Anker; C J Strasburger
Journal:  Eur J Endocrinol       Date:  2001-12       Impact factor: 6.664

5.  Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure.

Authors:  Noritoshi Nagaya; Junji Moriya; Yoshio Yasumura; Masaaki Uematsu; Fumiaki Ono; Wataru Shimizu; Kazuyuki Ueno; Masafumi Kitakaze; Kunio Miyatake; Kenji Kangawa
Journal:  Circulation       Date:  2004-11-29       Impact factor: 29.690

6.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

7.  Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure.

Authors:  Jarrad M Scarlett; Darren D Bowe; Xinxia Zhu; Ayesha K Batra; Wilmon F Grant; Daniel L Marks
Journal:  J Endocrinol       Date:  2010-04-06       Impact factor: 4.286

8.  Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins.

Authors:  M Ek; M Kurosawa; T Lundeberg; A Ericsson
Journal:  J Neurosci       Date:  1998-11-15       Impact factor: 6.167

Review 9.  Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies.

Authors:  Alessandro Laviano; Michael M Meguid; Filippo Rossi-Fanelli
Journal:  Lancet Oncol       Date:  2003-11       Impact factor: 41.316

10.  Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein.

Authors:  H Y Chen; M E Trumbauer; A S Chen; D T Weingarth; J R Adams; E G Frazier; Z Shen; D J Marsh; S D Feighner; X-M Guan; Z Ye; R P Nargund; R G Smith; L H T Van der Ploeg; A D Howard; D J MacNeil; S Qian
Journal:  Endocrinology       Date:  2004-02-12       Impact factor: 4.736

View more
  2 in total

1.  A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol.

Authors:  David P Kao; Brandie D Wagner; Alastair D Robertson; Michael R Bristow; Brian D Lowes
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

2.  Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease.

Authors:  Jenny Wilshaw; Steven L Rosenthal; Gerhard Wess; Dave Dickson; Luca Bevilacqua; Emily Dutton; Michael Deinert; Ricardo Abrantes; Ingo Schneider; Mark A Oyama; Sonya G Gordon; Jonathan Elliott; Dong Xia; Adrian Boswood
Journal:  J Vet Intern Med       Date:  2021-03-01       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.